(Q60922380)

English

Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores

No description defined

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores (English)

0 references

phase III clinical trial

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pancreatic cancer

1 reference

based on heuristic

inferred from title

object named as

Piera Gargiulo

1

0 references

Bengt Glimelius

7

object named as

Bengt Glimelius

0 references

author name string

Daniel Dietrich

2

0 references

Richard Herrmann

3

0 references

György Bodoky

4

0 references

Thomas Ruhstaller

5

0 references

Werner Scheithauer

6

0 references

Simona Berardi

8

0 references

Sandro Pignata

9

0 references

Peter Brauchli

10

0 references

language of work or name

0 references

publication date

2019

0 references

Therapeutic advances in medical oncology

0 references

11

0 references

1758835918818351

0 references

Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of clinicopathological characteristics in patients with pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Neutrophil-Platelet Score (NPS) Predicts Survival in Primary Operable Colorectal Cancer and a Variety of Common Cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP).

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30636977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1177/1758835918818351

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q60922380&oldid=1540401424"